{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:51:22Z","timestamp":1780044682576,"version":"3.53.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.annonc.2022.04.073","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T21:19:16Z","timestamp":1651699156000},"page":"850-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference"],"prefix":"10.1016","volume":"33","author":[{"given":"M.","family":"Launay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Balluet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Phelip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tholance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gonzalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.annonc.2022.04.073_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"[Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2022.04.073_bib2","doi-asserted-by":"crossref","first-page":"100125","DOI":"10.1016\/j.esmoop.2021.100125","article-title":"Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature","volume":"6","author":"Hodroj","year":"2021","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.annonc.2022.04.073_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bulcan.2019.04.013","article-title":"[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: results of two national practice surveys addressed to clinicians and biologists]","volume":"106","author":"Loriot","year":"2019","journal-title":"Bull Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2022.04.073_bib4","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00280-021-04354-7","article-title":"Pretherapeutic screening for dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results","volume":"88","author":"Gaible","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.annonc.2022.04.073_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.annonc.2022.04.073_bib6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2022.04.073_bib7","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.4081\/rt.2014.5389","article-title":"Tumor lysis syndrome in solid tumors: an up to date review of the literature","volume":"6","author":"Mirrakhimov","year":"2014","journal-title":"Rare Tumors"},{"issue":"1","key":"10.1016\/j.annonc.2022.04.073_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000441-200301000-00008","article-title":"Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?","volume":"325","author":"Vaisban","year":"2003","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.annonc.2022.04.073_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5492\/wjccm.v4.i2.130","article-title":"Tumor lysis syndrome: a clinical review","volume":"4","author":"Mirrakhimov","year":"2015","journal-title":"World J Crit Care Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422007633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422007633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:10:01Z","timestamp":1760335801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422007633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0923753422007633"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.04.073","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.04.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}